$QURE +66% Premarket 🚀 🔹 Massive move after FDA agreed existing trial data could support accelerated approval filing 📈 🔹 UniQure is developing a gene therap

$QURE +66% Premarket 🚀 🔹 Massive move after FDA agreed existing trial data could support accelerated approval filing 📈 🔹 UniQure is developing a gene therapy for Huntington’s disease — a devastating neurodegenerative condition 🧬 🔹 FDA said 3-year data from its early-to-mid-stage trial may be e…